Yi-Long Wu (Yilong Wu)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 91

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Signal transduction and targeted therapy

Nature communications

Future oncology (London, England)

Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences Dec 26 2002

China

Professor :: Guangdong Lung Cancer Institute

Publications

David R Spigel, Afshin Dowlati, Yuanbin Chen, Alejandro Navarro, James Chih-Hsin Yang, Goran Stojanovic, Maria Jove, Patricia Rich, Zoran G Andric, Yi-Long Wu, Charles M Rudin, Huanyu Chen, Li Zhang, Stanley Yeung, Fawzi Benzaghou, Luis G Paz-Ares, Paul A Bunn, null null
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Jin-Ji Yang, Yan Zhang, Lin Wu, Jie Hu, Zhe-Hai Wang, Jing-Hua Chen, Yun Fan, Gen Lin, Qi-Ming Wang, Yu Yao, Jun Zhao, Yuan Chen, Jian Fang, Yong Song, Wei Zhang, Ying Cheng, Ren-Hua Guo, Xing-Ya Li, He-Peng Shi, Wei-Zhe Xue, Di Han, Pei-Long Zhang, Yi-Long Wu
Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Tony S K Mok, Kazuhiko Nakagawa, Keunchil Park, Yuichiro Ohe, Nicolas Girard, Hye Ryun Kim, Yi-Long Wu, Justin F Gainor, Se-Hoon Lee, Chao-Hua Chiu, Sang-We Kim, Cheng-Ta Yang, Chien Liang Wu, Lin Wu, Meng-Chih Lin, Jens Samol, Kazuya Ichikado, Mengzhao Wang, Xiaoqing Zhang, Judi Sylvester, Sunney Li, Ann Forslund, James Chih-Hsin Yang
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Tony S K Mok, Kazuhiko Nakagawa, Keunchil Park, Yuichiro Ohe, Nicolas Girard, Hye Ryun Kim, Yi-Long Wu, Justin F Gainor, Se-Hoon Lee, Chao-Hua Chiu, Sang-We Kim, Cheng-Ta Yang, Chien Liang Wu, Lin Wu, Meng-Chih Lin, Jens Samol, Kazuya Ichikado, Mengzhao Wang, Xiaoqing Zhang, Judi Sylvester, Sunney Li, Ann Forslund, James Chih-Hsin Yang
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (11) (2024)
David R Spigel, Afshin Dowlati, Yuanbin Chen, Alejandro Navarro, James Chih-Hsin Yang, Goran Stojanovic, Maria Jove, Patricia Rich, Zoran G Andric, Yi-Long Wu, Charles M Rudin, Huanyu Chen, Li Zhang, Stanley Yeung, Fawzi Benzaghou, Luis G Paz-Ares, Paul A Bunn, null null
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Tony S K Mok, Kazuhiko Nakagawa, Keunchil Park, Yuichiro Ohe, Nicolas Girard, Hye Ryun Kim, Yi-Long Wu, Justin F Gainor, Se-Hoon Lee, Chao-Hua Chiu, Sang-We Kim, Cheng-Ta Yang, Chien Liang Wu, Lin Wu, Meng-Chih Lin, Jens Samol, Kazuya Ichikado, Mengzhao Wang, Xiaoqing Zhang, Judi Sylvester, Sunney Li, Ann Forslund, James Chih-Hsin Yang
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (11) (2024)
David R Spigel, Afshin Dowlati, Yuanbin Chen, Alejandro Navarro, James Chih-Hsin Yang, Goran Stojanovic, Maria Jove, Patricia Rich, Zoran G Andric, Yi-Long Wu, Charles M Rudin, Huanyu Chen, Li Zhang, Stanley Yeung, Fawzi Benzaghou, Luis G Paz-Ares, Paul A Bunn, null null
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Benjamin J Solomon, Geoffrey Liu, Enriqueta Felip Font, Tony S K Mok, Ross Andrew Soo, Julien Mazieres, Alice T Shaw, Filippo de Marinis, Yasushi Goto, Yi-Long Wu, Dong Wan Kim, Jean-Francois Martini, Rossella Messina, Jolanda Paolini, Anna Polli, Despina Thomaidou, Francesca Toffalorio, Todd M Bauer
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
David R Spigel, Afshin Dowlati, Yuanbin Chen, Alejandro Navarro, James Chih-Hsin Yang, Goran Stojanovic, Maria Jove, Patricia Rich, Zoran G Andric, Yi-Long Wu, Charles M Rudin, Huanyu Chen, Li Zhang, Stanley Yeung, Fawzi Benzaghou, Luis G Paz-Ares, Paul A Bunn, null null
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
David R Spigel, Afshin Dowlati, Yuanbin Chen, Alejandro Navarro, James Chih-Hsin Yang, Goran Stojanovic, Maria Jove, Patricia Rich, Zoran G Andric, Yi-Long Wu, Charles M Rudin, Huanyu Chen, Li Zhang, Stanley Yeung, Fawzi Benzaghou, Luis G Paz-Ares, Paul A Bunn, null null
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Yi-Long Wu, Rafal Dziadziuszko, Jin Seok Ahn, Fabrice Barlesi, Makoto Nishio, Dae Ho Lee, Jong-Seok Lee, Wenzhao Zhong, Hidehito Horinouchi, Weimin Mao, Maximilian Hochmair, Filippo de Marinis, M Rita Migliorino, Igor Bondarenko, Shun Lu, Qun Wang, Tania Ochi Lohmann, Tingting Xu, Andres Cardona, Thorsten Ruf, Johannes Noe, Benjamin J Solomon, null null
Alectinib in Resected ALK -Positive Non-Small-Cell Lung Cancer. The New England journal of medicine 390 (14) (2024)
Tony S K Mok, Kazuhiko Nakagawa, Keunchil Park, Yuichiro Ohe, Nicolas Girard, Hye Ryun Kim, Yi-Long Wu, Justin F Gainor, Se-Hoon Lee, Chao-Hua Chiu, Sang-We Kim, Cheng-Ta Yang, Chien Liang Wu, Lin Wu, Meng-Chih Lin, Jens Samol, Kazuya Ichikado, Mengzhao Wang, Xiaoqing Zhang, Judi Sylvester, Sunney Li, Ann Forslund, James Chih-Hsin Yang
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (11) (2024)
David R Spigel, Afshin Dowlati, Yuanbin Chen, Alejandro Navarro, James Chih-Hsin Yang, Goran Stojanovic, Maria Jove, Patricia Rich, Zoran G Andric, Yi-Long Wu, Charles M Rudin, Huanyu Chen, Li Zhang, Stanley Yeung, Fawzi Benzaghou, Luis G Paz-Ares, Paul A Bunn, null null
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
David R Spigel, Afshin Dowlati, Yuanbin Chen, Alejandro Navarro, James Chih-Hsin Yang, Goran Stojanovic, Maria Jove, Patricia Rich, Zoran G Andric, Yi-Long Wu, Charles M Rudin, Huanyu Chen, Li Zhang, Stanley Yeung, Fawzi Benzaghou, Luis G Paz-Ares, Paul A Bunn, null null
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Tony S K Mok, Kazuhiko Nakagawa, Keunchil Park, Yuichiro Ohe, Nicolas Girard, Hye Ryun Kim, Yi-Long Wu, Justin F Gainor, Se-Hoon Lee, Chao-Hua Chiu, Sang-We Kim, Cheng-Ta Yang, Chien Liang Wu, Lin Wu, Meng-Chih Lin, Jens Samol, Kazuya Ichikado, Mengzhao Wang, Xiaoqing Zhang, Judi Sylvester, Sunney Li, Ann Forslund, James Chih-Hsin Yang
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Tony S K Mok, Kazuhiko Nakagawa, Keunchil Park, Yuichiro Ohe, Nicolas Girard, Hye Ryun Kim, Yi-Long Wu, Justin F Gainor, Se-Hoon Lee, Chao-Hua Chiu, Sang-We Kim, Cheng-Ta Yang, Chien Liang Wu, Lin Wu, Meng-Chih Lin, Jens Samol, Kazuya Ichikado, Mengzhao Wang, Xiaoqing Zhang, Judi Sylvester, Sunney Li, Ann Forslund, James Chih-Hsin Yang
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (11) (2024)
Yi-Long Wu, Rafal Dziadziuszko, Jin Seok Ahn, Fabrice Barlesi, Makoto Nishio, Dae Ho Lee, Jong-Seok Lee, Wenzhao Zhong, Hidehito Horinouchi, Weimin Mao, Maximilian Hochmair, Filippo de Marinis, M Rita Migliorino, Igor Bondarenko, Shun Lu, Qun Wang, Tania Ochi Lohmann, Tingting Xu, Andres Cardona, Thorsten Ruf, Johannes Noe, Benjamin J Solomon, null null
Alectinib in Resected ALK -Positive Non-Small-Cell Lung Cancer. The New England journal of medicine 390 (14) (2024)
Tony S K Mok, Kazuhiko Nakagawa, Keunchil Park, Yuichiro Ohe, Nicolas Girard, Hye Ryun Kim, Yi-Long Wu, Justin F Gainor, Se-Hoon Lee, Chao-Hua Chiu, Sang-We Kim, Cheng-Ta Yang, Chien Liang Wu, Lin Wu, Meng-Chih Lin, Jens Samol, Kazuya Ichikado, Mengzhao Wang, Xiaoqing Zhang, Judi Sylvester, Sunney Li, Ann Forslund, James Chih-Hsin Yang
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (11) (2024)
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Jun Wang, Xue-Ning Yang, Wei-Min Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng, Lin Xu, Chang-Li Wang, Ming-Wei Chen, Xiao-Zheng Kang, Wan-Pu Yan, Ri-Qiang Liao, Jin-Ji Yang, Xu-Chao Zhang, Si-Yang Liu, Qing Zhou, Yi-Long Wu
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal transduction and targeted therapy 8 (1) (2023)
Guang-Ling Jie, Lun-Xi Peng, Mei-Mei Zheng, Hao Sun, Song-Rong Wang, Si-Yang Maggie Liu, Kai Yin, Zhi-Hong Chen, Hong-Xia Tian, Jin-Ji Yang, Xu-Chao Zhang, Hai-Yan Tu, Qing Zhou, Catherine C L Wong, Yi-Long Wu
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC. Cancers 15 (1) (2023)
Ji Zhou, Xu-Chao Zhang, Shan Xue, Mengdi Dai, Yueliang Wang, Xia Peng, Jianjiao Chen, Xinyi Wang, Yanyan Shen, Hui Qin, Bi Chen, Yu Zheng, Xiwen Gao, Zuoquan Xie, Jian Ding, Handong Jiang, Yi-Long Wu, Meiyu Geng, Jing Ai
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer. Signal transduction and targeted therapy 8 (1) (2023)
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh R Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A Shepherd, Krishna C Bulusu, Gianluca Laus, Barbara Collins, J Carl Barrett, Ryan J Hartmaier, Vassiliki A Papadimitrakopoulou
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications 14 (1) (2023)
Si-Yang Maggie Liu, Cunte Chen, Yi-Kai Zhang, Wen-Zhao Zhong, Yi-Long Wu, Si-Yang Liu, Yangqiu Li
Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer. Biomarker research 11 (1) (2023)
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Jun Wang, Xue-Ning Yang, Wei-Min Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng, Lin Xu, Chang-Li Wang, Ming-Wei Chen, Xiao-Zheng Kang, Wan-Pu Yan, Ri-Qiang Liao, Jin-Ji Yang, Xu-Chao Zhang, Si-Yang Liu, Qing Zhou, Yi-Long Wu
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal transduction and targeted therapy 8 (1) (2023)
Parneet Cheema, Byoung Chul Cho, Helano Freitas, Mariano Provencio, Yuh Min Chen, Sang-We Kim, Yi-Long Wu, Antonio Passaro, Claudio Martin, Marcello Tiseo, Gee-Chen Chang, Keunchil Park, Benjamin Solomon, Otto Burghuber, Janessa Laskin, Ziping Wang, Sung Yong Lee, Yanping Hu, Johan Vansteenkiste, He-Long Zhang, Emer Hanrahan, Thomas Geldart, Rosemary Taylor, Leslie Servidio, Jingyi Li, Filippo de Marinis
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data. Future oncology (London, England) (2023)
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Jun Wang, Xue-Ning Yang, Wei-Min Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng, Lin Xu, Chang-Li Wang, Ming-Wei Chen, Xiao-Zheng Kang, Wan-Pu Yan, Ri-Qiang Liao, Jin-Ji Yang, Xu-Chao Zhang, Si-Yang Liu, Qing Zhou, Yi-Long Wu
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal transduction and targeted therapy 8 (1) (2023)
Si-Yang Maggie Liu, Cunte Chen, Yi-Kai Zhang, Wen-Zhao Zhong, Yi-Long Wu, Si-Yang Liu, Yangqiu Li
Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer. Biomarker research 11 (1) (2023)
Qing Zhou, Jun Zhao, Jianhua Chang, Huijie Wang, Yun Fan, Ke Wang, Gang Wu, Weiqi Nian, Yuping Sun, Meili Sun, Xiangcai Wang, Huaqiu Shi, Xiangqian Zheng, Sheng Yao, Mengmeng Qin, Zhenwei Shen, Jason Yang, Yi-Long Wu
Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer. Cancer (2023)
Guang-Ling Jie, Lun-Xi Peng, Mei-Mei Zheng, Hao Sun, Song-Rong Wang, Si-Yang Maggie Liu, Kai Yin, Zhi-Hong Chen, Hong-Xia Tian, Jin-Ji Yang, Xu-Chao Zhang, Hai-Yan Tu, Qing Zhou, Catherine C L Wong, Yi-Long Wu
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC. Cancers 15 (1) (2023)
Yi-Long Wu, Qing Zhou
Combination Therapy for EGFR -Mutated Lung Cancer. The New England journal of medicine (2023)
Ji Zhou, Xu-Chao Zhang, Shan Xue, Mengdi Dai, Yueliang Wang, Xia Peng, Jianjiao Chen, Xinyi Wang, Yanyan Shen, Hui Qin, Bi Chen, Yu Zheng, Xiwen Gao, Zuoquan Xie, Jian Ding, Handong Jiang, Yi-Long Wu, Meiyu Geng, Jing Ai
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer. Signal transduction and targeted therapy 8 (1) (2023)
Helena Alexandra Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip Font, James Chih-Hsin Yang, Martin Reck, Kiyotaka Yoh, Se-Hoon Lee, Luis G Paz-Ares, Benjamin Besse, Paolo Bironzo, Dong Wan Kim, Melissa Lynne Johnson, Yi-Long Wu, Thomas John, Steven Kao, Toshiyuki Kozuki, Erminia Massarelli, Jyoti D Patel, Egbert F Smit, Karen L Reckamp, Qian Dong, Pomy Shrestha, Pang-Dian Fan, Parul Patel, Andrea Sporchia, David W Sternberg, Dalila Sellami, Pasi A Janne
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Si-Yang Maggie Liu, Hai-Yan Tu, Xue-Wu Wei, Hong-Hong Yan, Xiao-Rong Dong, Jiu-Wei Cui, Zhen Zhou, Chong-Rui Xu, Ming-Ying Zheng, Yang-Si Li, Zhen Wang, Xiao-Yan Bai, An-Na Li, Yue-Li Sun, Jie Huang, Jia-Xin Lin, E E Ke, Bing-Fei Xu, Chang Lu, Yingying Du, Yuan Chen, Rui Ma, Bu-Hai Wang, Shun-Dong Cang, Bin-Chao Wang, Hua-Jun Chen, Jin-Ji Yang, Yangqiu Li, Qing Zhou, Yi-Long Wu
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial. Nature medicine (2023)
Jun Zhao, Xinmin Yu, Dingzhi Huang, Zhiyong Ma, Bo Gao, Jiuwei Cui, Qian Chu, Qing Zhou, Meili Sun, Daphne Day, Jingxun Wu, Hongming Pan, Lifeng Wang, Mark Voskoboynik, Zhehai Wang, Yunpeng Liu, Hui Li, Juan Zhang, Yanyan Peng, Yi-Long Wu
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. Journal for immunotherapy of cancer 11 (2) (2023)
Chong-Kin Liam, Azura Rozila Ahmad, Te-Chun Hsia, Jian-Ying Zhou, Dong Wan Kim, Ross Andrew Soo, Ying Cheng, Shun Lu, Sang Won Shin, James Chih-Hsin Yang, Yiping Zhang, Jun Zhao, Karin Berghoff, Rolf Bruns, Andreas Johne, Yi-Long Wu
Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Hai-Yan Tu, Kai Yin, Xiaotian Zhao, E-E Ke, Si-Pei Wu, Yang-Si Li, Mei-Mei Zheng, Si-Yang Maggie Liu, Chong-Rui Xu, Yue-Li Sun, Jia-Xin Lin, Xiao-Yan Bai, Yi-Chen Zhang, Qing Zhou, Jin-Ji Yang, Wen-Zhao Zhong, Bing-Chao Wang, Xu-Chao Zhang, Dongqin Zhu, Lingling Yang, Qiuxiang Ou, Yi-Long Wu
Genomic and immune characteristics of HER2-mutated non-small cell lung cancer and response to immune checkpoint inhibitor-based therapy. Molecular oncology (2023)
Jhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, Frances A Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng-Chih Lin, Yi-Long Wu, Margarita Majem Tarruella, Oliver Gautschi, Michael J Boyer, Krishna C Bulusu, Aleksandra A Markovets, J Carl Barrett, Rachel Hodge, Astrid McKeown, Ryan J Hartmaier, Juliann Chmielecki, Vassiliki A Papadimitrakopoulou, Suresh R Ramalingam
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Roy S Herbst, Yi-Long Wu, Masahiro Tsuboi
Reply to D. Wu et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Guang-Ling Jie, Lun-Xi Peng, Mei-Mei Zheng, Hao Sun, Song-Rong Wang, Si-Yang Maggie Liu, Kai Yin, Zhi-Hong Chen, Hong-Xia Tian, Jin-Ji Yang, Xu-Chao Zhang, Hai-Yan Tu, Qing Zhou, Catherine C L Wong, Yi-Long Wu
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC. Cancers 15 (1) (2023)
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh R Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A Shepherd, Krishna C Bulusu, Gianluca Laus, Barbara Collins, J Carl Barrett, Ryan J Hartmaier, Vassiliki A Papadimitrakopoulou
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications 14 (1) (2023)
Guang-Ling Jie, Lun-Xi Peng, Mei-Mei Zheng, Hao Sun, Song-Rong Wang, Si-Yang Maggie Liu, Kai Yin, Zhi-Hong Chen, Hong-Xia Tian, Jin-Ji Yang, Xu-Chao Zhang, Hai-Yan Tu, Qing Zhou, Catherine C L Wong, Yi-Long Wu
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC. Cancers 15 (1) (2023)
Jia-Yi Deng, Qing Gou, Lingling Yang, Zhi-Hong Chen, Ming-Yi Yang, Xiao-Rong Yang, Hong-Hong Yan, Xue-Wu Wei, Jia-Qi Liu, Jian Su, Wen-Zhao Zhong, Chong-Rui Xu, Yi-Long Wu, Qing Zhou
Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer. Journal for immunotherapy of cancer 11 (7) (2023)
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Jun Wang, Xue-Ning Yang, Wei-Min Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng, Lin Xu, Chang-Li Wang, Ming-Wei Chen, Xiao-Zheng Kang, Wan-Pu Yan, Ri-Qiang Liao, Jin-Ji Yang, Xu-Chao Zhang, Si-Yang Liu, Qing Zhou, Yi-Long Wu
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal transduction and targeted therapy 8 (1) (2023)
Si-Yang Maggie Liu, Cunte Chen, Yi-Kai Zhang, Wen-Zhao Zhong, Yi-Long Wu, Si-Yang Liu, Yangqiu Li
Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer. Biomarker research 11 (1) (2023)
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh R Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A Shepherd, Krishna C Bulusu, Gianluca Laus, Barbara Collins, J Carl Barrett, Ryan J Hartmaier, Vassiliki A Papadimitrakopoulou
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications 14 (1) (2023)
Roy S Herbst, Yi-Long Wu, Thomas John, Christian Grohe, Margarita Majem, Jie Wang, Terufumi Kato, Jonathan Wade Goldman, Konstantin Laktionov, Sang-We Kim, Chong-Jen Yu, Huu Vinh Vu, Shun Lu, Kye Young Lee, Guzel Mukhametshina, Charuwan Akewanlop, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A Shepherd, Damien Urban, Xiangning Huang, Ana Bolanos, Marta Stachowiak, Masahiro Tsuboi
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Jun Wang, Xue-Ning Yang, Wei-Min Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng, Lin Xu, Chang-Li Wang, Ming-Wei Chen, Xiao-Zheng Kang, Wan-Pu Yan, Ri-Qiang Liao, Jin-Ji Yang, Xu-Chao Zhang, Si-Yang Liu, Qing Zhou, Yi-Long Wu
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal transduction and targeted therapy 8 (1) (2023)
Byoung Chul Cho, Myung-Ju Ahn, Jin Hyoung Kang, Ross Andrew Soo, Thanyanan Reungwetwattana, James Chih-Hsin Yang, Irfan Cicin, Dong Wan Kim, Yi-Long Wu, Shun Lu, Ki Hyeong Lee, Yong-Kek Pang, Anastasia Zimina, Chin Heng Fong, Elena Poddubskaya, Ahmet Sezer, Soon Hin How, Pongwut Danchaivijitr, YuKyung Kim, Yeji Lim, Taewon An, Hana Lee, Hae Mi Byun, Bojan Zarić
Lazertinib Versus Gefitinib as First-line Treatment in Patients With EGFR -mutated Advanced Non-Small Cell Lung Cancer (NSCLC): Results From LASER301. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Ji Zhou, Xu-Chao Zhang, Shan Xue, Mengdi Dai, Yueliang Wang, Xia Peng, Jianjiao Chen, Xinyi Wang, Yanyan Shen, Hui Qin, Bi Chen, Yu Zheng, Xiwen Gao, Zuoquan Xie, Jian Ding, Handong Jiang, Yi-Long Wu, Meiyu Geng, Jing Ai
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer. Signal transduction and targeted therapy 8 (1) (2023)
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Jun Wang, Xue-Ning Yang, Wei-Min Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng, Lin Xu, Chang-Li Wang, Ming-Wei Chen, Xiao-Zheng Kang, Wan-Pu Yan, Ri-Qiang Liao, Jin-Ji Yang, Xu-Chao Zhang, Si-Yang Liu, Qing Zhou, Yi-Long Wu
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal transduction and targeted therapy 8 (1) (2023)
Si-Yang Liu, Song Dong, Xue-Ning Yang, Ri-Qiang Liao, Ben-Yuan Jiang, Qun Wang, Xiao-Song Ben, Gui-Bin Qiao, Jun-Tao Lin, Hong-Hong Yan, Li-Xu Yan, Qiang Nie, Hai-Yan Tu, Bin-Chao Wang, Jin-Ji Yang, Qing Zhou, Hong-Rui Li, Ke Liu, Wendy Wu, Si-Yang Maggie Liu, Wen-Zhao Zhong, Yi-Long Wu
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study. Signal transduction and targeted therapy 8 (1) (2023)
Jianxin Shi, Kouya Shiraishi, Jiyeon Choi, Keitaro Matsuo, Tzu-Yu Chen, Juncheng Dai, Rayjean J Hung, Kexin Chen, Xiao-Ou Shu, Young Tae Kim, Maria Teresa Landi, Dongxin Lin, Quan Long, Zhihua Yin, Bao Sen Zhou, Bao Song, Jiucun Wang, Wei Jie Seow, Lei Song, I-Shou Chang, Wei Hu, Li-Hsin Chien, Qiuyin Cai, Yun-Chul Hong, Hee Nam Kim, Yi-Long Wu, Maria Pik Wong, Brian Douglas Richardson, Karen M Funderburk, Shilan Li, Tongwu Zhang, Charles Breeze, Zhaoming Wang, Batel Blechter, Bryan A Bassig, Jin Hee Kim, Demetrios Albanes, Jason Y Y Wong, Min-Ho Shin, Lap Ping Chung, Yang Yang, She-Juan An, Hong Zheng, Yasushi Yatabe, Xu Chao Zhang, Young-Chul Kim, Neil E Caporaso, Jiang Chang, Chung Man James Ho, Michiaki Kubo, Yataro Daigo, Minsun Song, Yukihide Momozawa, Yoichiro Kamatani, Masashi Kobayashi, Kenichi Okubo, Takayuki Honda, Dean H Hosgood, Hideo Kunitoh, Harsh Patel, Shun-Ichi Watanabe, Yohei Miyagi, Haruhiko Nakayama, Shingo Matsumoto, Hidehito Horinouchi, Masahiro Tsuboi, Ryuji Hamamoto, Koichi Goto, Yuichiro Ohe, Atsushi Takahashi, Akiteru Goto, Yoshihiro Minamiya, Megumi Hara, Yuichiro Nishida, Kenji Takeuchi, Kenji Wakai, Koichi Matsuda, Yoshinori Murakami, Kimihiro Shimizu, Hiroyuki Suzuki, Katsuharu Saito, Yoichi Ohtaki, Kazumi Tanaka, Tangchun Wu, Fusheng Wei, Hongji Dai, Mitchell J Machiela, Jian Su, Yeul Hong Kim, In Jae Oh, Victor Ho Fun Lee, Gee-Chen Chang, Ying-Huang Tsai, Kuan-Yu Chen, Ming-Shyan Huang, Wu-Chou Su, Yuh-Min Chen, Adeline Seow, Jae Yong Park, Sun-Seog Kweon, Kun-Chieh Chen, Yu-Tang Gao, Biyun Qian, Chen Wu, Daru Lu, Jian-Jun Liu, Ann G Schwartz, Richard S Houlston, Margaret R Spitz, Ivan P Gorlov, Xifeng Wu, Ping Yang, Stephen Lam, Adonina Tardón, Chu Chen, Stig Egil Bojesen, Mattias J Johansson, Angela Risch, Heike Bickeböller, Bu-Tian Ji, H-Erich Wichmann, David Chistopher Christiani, Gadi Rennert, Susanne M Arnold, Paul Brennan, James McKay, John K Field, Sanjay S Shete, Loic Le Marchand, Geoffrey Liu, Angeline Andrew, Lambertus A L M Kiemeney, Shan Zienolddiny-Narui, Kjell Grankvist, Mikael Johansson, Angela Cox, Fiona Taylor, Woon-Puay Koh, Philip Lazarus, Matthew B Schabath, Melinda C Aldrich, Hyo-Sung Jeon, Shih Sheng Jiang, Jae Sook Sung, Chung-Hsing Chen, Chin-Fu Hsiao, Yoo Jin Jung, Huan Guo, Zhi-Bin Hu, Laurie Burdett, Meredith Yeager, Amy Hutchinson, Belynda D Hicks, Jia Liu, Bin Zhu, Sonja I Berndt, Wei Wu, Junwen Wang, Yuqing Li, Jin Eun Choi, Kyong Hwa Park, Sook Whan Sung, Li Liu, Chang Hyun Kang, Wen-Chang Wang, Jun Xu, Peng Guan, Wen Tan, Chong-Jen Yu, Gong Yang, Alan Dart Loon Sihoe, Ying Chen, Yi Young Choi, Jun Suk Kim, Ho-Il Yoon, In Kyu Park, Ping Xu, Qincheng He, Chih-Liang Wang, Hsiao-Han Hung, Roel C H Vermeulen, Iona Cheng, Junjie Wu, Wei-Yen Lim, Fang-Yu Tsai, John K C Chan, Jihua Li, Hongyan Chen, Hsien-Chih Lin, Li Jin, Jie Liu, Norie Sawada, Taiki Yamaji, Kathleen Wyatt, Shengchao A Li, Hongxia Ma, Meng Zhu, Zhehai Wang, Sensen Cheng, Xuelian Li, Yangwu Ren, Ann Chao, Motoki Iwasaki, Junjie Zhu, Gening Jiang, Ke Fei, Guoping Wu, Chih-Yi Chen, Chien-Jen Chen, Pan-Chyr Yang, Jinming Yu, Victoria L Stevens, Joseph F Fraumeni, Nilanjan Chatterjee, Olga Y Gorlova, Chao Agnes Hsiung, Christopher Ian Amos, Hongbing Shen, Stephen J Chanock, Nathaniel Rothman, Takashi Kohno, Qing Lan
Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population. Nature communications 14 (1) (2023)
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh R Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A Shepherd, Krishna C Bulusu, Gianluca Laus, Barbara Collins, J Carl Barrett, Ryan J Hartmaier, Vassiliki A Papadimitrakopoulou
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications 14 (1) (2023)
Cunte Chen, Si-Yang Maggie Liu, Yuchen Han, Ming Han, Qiuxiang Ou, Hua Bao, Ling Xu, Yi-Kai Zhang, Wen-Zhao Zhong, Wen-Zhao Zhong, Qing Zhou, Xue-Ning Yang, Yang W Shao, Yi-Long Wu, Si-Yang Liu, Yangqiu Li
Poor prognosis of intra-tumoural TRBV6-6 variants in EGFR-mutant NSCLC: Results from the ADJUVANT-CTONG1104 trial. Clinical and translational medicine 12 (4) (2022)
Hai-Yan Tu, Jifeng Feng, Meiqi Shi, Jun Zhao, Yuyan Wang, Jianhua Chang, Jialei Wang, Ying Cheng, Jing Zhu, Eng-Huat Tan, Kai Li, Yiping Zhang, Victor Lee, Cheng-Ta Yang, Wu-Chou Su, David Chi-Leung Lam, B J Srinivasa, Senthil Rajappa, Ching-Liang Ho, Kwok Chi Lam, Yi Hu, Shailesh Arjun Bondarde, Xiaoqing Liu, Yahui Tian, Zhiyi Xue, Agnieszka Cseh, Dennis Chin-Lun Huang, Caicun Zhou, Yi-Long Wu
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. Targeted oncology 17 (1) (2022)
Bob T Li, Bobby Daly, Mary Gospodarowicz, Monica M Bertagnolli, Otis W Brawley, Bruce A Chabner, Lola Fashoyin-Aje, R Angelo de Claro, Elizabeth Franklin, Jennifer Mills, Jeff Legos, Karen Kaucic, Mark Li, Lydia The, Tina Hou, Ting-Hui Wu, Bjorn Albrecht, Yi Shao, Justin Finnegan, Jing Qian, Javad Shahidi, Eduard Gasal, Craig Tendler, Geoffrey Kim, James Yan, Phuong Khanh Morrow, Charles S Fuchs, Lianshan Zhang, Robert LaCaze, Stefan Oelrich, Martin J Murphy, Richard Pazdur, Kevin Rudd, Yi-Long Wu
Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition. Nature medicine 28 (4) (2022)
Lei Yang, Yun-Ting He, Song Dong, Xue-Wu Wei, Zhi-Hong Chen, Bo Zhang, Wei-Dong Chen, Xiao-Rong Yang, Fen Wang, Xue-Meng Shang, Wen-Zhao Zhong, Yi-Long Wu, Qing Zhou
Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma. Journal for immunotherapy of cancer 10 (2) (2022)
Wen-Zhao Zhong, Si-Yang Liu, Wei Gao, Si-Yang Maggie Liu, Hong-Hong Yan, Liyan Ji, Yu Chen, Yuhua Gong, Hong-Lian Lu, Jun-Tao Lin, Kai Yin, Ben-Yuan Jiang, Qiang Nie, Ri-Qiang Liao, Song Dong, Yanfang Guan, Pingping Dai, Xu Chao Zhang, Jin-Ji Yang, Hai-Yan Tu, Xuefeng Xia, Xin Yi, Qing Zhou, Wen-Zhao Zhong, Xue-Ning Yang, Yi-Long Wu
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer. Cancer discovery 12 (7) (2022)
Margarita Majem Tarruella, Jonathan Wade Goldman, Thomas John, Christian Grohe, Konstantin Laktionov, Sang-We Kim, Terufumi Kato, Huu Vinh Vu, Shun Lu, Shanqing Li, Kye Young Lee, Charuwan Akewanlop, Chong-Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A Shepherd, Shinji Atagi, Lingmin Zeng, Dakshayini Kulkarni, Nenad Medic, Masahiro Tsuboi, Roy S Herbst, Yi-Long Wu
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (11) (2022)
Gilberto de Castro Junior, Iveta Kudaba, Yi-Long Wu, Gilberto de Lima Lopes, Dariusz Mirosław Kowalski, Hande Z Turna, Christian Caglevic, Li Zhang, Boguslawa Karaszewska, Konstantin K Laktionov, Vichien Srimuninnimit, Igor Bondarenko, Kaoru Kubota, Rinee Mukherjee, Jianxin Lin, Fabricio Souza, Tony S K Mok, Byoung Chul Cho
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Benjamin J Solomon, Todd M Bauer, Sai-Hong Ignatius Ou, Geoffrey Liu, Hidetoshi Hayashi, Alessandra Bearz, Konstantin Penkov, Yi-Long Wu, Arrieta Oscar, Jacek Jassem, Anna M Calella, Gerson Peltz, Anna Polli, Holger Thurm, Tony S K Mok
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK -Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (31) (2022)
David R Spigel, Corinne Faivre-Finn, Jhanelle E Gray, David Vicente, David Planchard, Luis G Paz-Ares, Johan Filip Vansteenkiste, Marina-Chiara Garassino, Rina Hui, Xavier Quantin, Andreas Rimner, Yi-Long Wu, Mustafa Özgüroğlu, Ki Hyeong Lee, Terufumi Kato, Maike de Wit, Takayasu Kurata, Martin Reck, Byoung Chul Cho, Suresh Senan, Jarushka Naidoo, Helen Mann, Michael Newton, Piruntha Thiyagarajah, Scott J Antonia
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (12) (2022)
Mei-Mei Zheng, Yang-Si Li, Hai-Yan Tu, Hao Sun, Kai Yin, Ben-Yuan Jiang, Jin-Ji Yang, Xu-Chao Zhang, Qing Zhou, Chong-Rui Xu, Zhen Wang, Hua-Jun Chen, De-Xiang Zhou, Yi-Long Wu
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases. BMC medicine 20 (1) (2022)
Si-Yang Liu, Si-Yang Maggie Liu, Wen-Zhao Zhong, Yi-Long Wu
Targeted Therapy in Early Stage Non-small Cell Lung Cancer. Current treatment options in oncology 23 (9) (2022)
Chao Zhang, Hua-Fei Chen, Shi Yan, Lin Wu, Li-Xu Yan, Xiao-Long Yan, Dong-Sheng Yue, Chun-Wei Xu, Min Zheng, Ji-Sheng Li, Si-Yang Liu, Ling-Ling Yang, Ben-Yuan Jiang, Qiu-Xiang Ou, Zhen-Bin Qiu, Yang Shao, Yi-Long Wu, Wen-Zhao Zhong
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis. NPJ precision oncology 6 (1) (2022)
Hong-Xia Tian, Zhi-Hong Chen, Guang-Ling Jie, Zhen Wang, Hong-Hong Yan, Si-Pei Wu, Shui-Lian Zhang, Dan-Xia Lu, Xu-Chao Zhang, Yi-Long Wu
Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients. Cancer medicine (2022)
Jun Zhao, Hua Bai, Xin Wang, Yuyan Wang, Jianchun Duan, Hanxiao Chen, Zhiyi Xue, Yahui Tian, Agnieszka Cseh, Dennis Chin-Lun Huang, Yi-Long Wu, Jie Wang
Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFR m+ non-small-cell lung cancer. Future oncology (London, England) 18 (12) (2022)
Jesus Corral, Tony S K Mok, Yi-Long Wu
Withdrawal of dacomitinib treatment due to absence of toxicities is not justified. Future oncology (London, England) (2022)
Masahiro Tsuboi, Jonathan W Goldman, Yi-Long Wu, Melissa L Johnson, Luis Paz-Ares, James Chih-Hsin Yang, Benjamin Besse, Weiji Su, Bo H Chao, Alexander Drilon
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer. Future oncology (London, England) 18 (28) (2022)
Yi-Long Wu, Ying Cheng, Huajun Chen, Hai-Yan Tu, Chong-Rui Xu, Zhen Wang, Ying Liu, Ying Xin, Haizhou Lou, Wei Wang, Kevin Chin, Dandan Li, Di Zhao, Yanfei Gao, Wenping Xu, Hongming Pan
Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors. Future oncology (London, England) 18 (17) (2022)
Cunte Chen, Si-Yang Maggie Liu, Yuchen Han, Qiuxiang Ou, Hua Bao, Ling Xu, Yi-Kai Zhang, Wen-Zhao Zhong, Wen-Zhao Zhong, Qing Zhou, Xue-Ning Yang, Yang W Shao, Yi-Long Wu, Si-Yang Liu, Yangqiu Li
Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial. Cancer immunology, immunotherapy : CII (2022)
Chao Zhang, Kai Yin, Si-Yang Liu, Li-Xu Yan, Jian Su, Yi-Long Wu, Xu-Chao Zhang, Wen-Zhao Zhong, Xue-Ning Yang
Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy. Journal for immunotherapy of cancer 9 (4) (2021)
Si-Yang Liu, Hua Bao, Qun Wang, Wei-Min Mao, Yuchen Han, Xiaoling Tong, Song-Tao Xu, Lin Wu, Yu-Cheng Wei, Yong-Yu Liu, Chun Chen, Ying Cheng, Rong Yin, Fan Yang, Sheng-Xiang Ren, Xiao-Fei Li, Jian Li, Cheng Huang, Zhi-Dong Liu, Shun Xu, Ke-Neng Chen, Shi-Dong Xu, Lun-Xu Liu, Ping Yu, Bu-Hai Wang, Hai-Tao Ma, Hong-Hong Yan, Song Dong, Xu Chao Zhang, Jian Su, Jin-Ji Yang, Xue-Ning Yang, Qing Zhou, Xue Wu, Yang W Shao, Wen-Zhao Zhong, Yi-Long Wu
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nature communications 12 (1) (2021)
Xue Bai, De-Hua Wu, Si-Cong Ma, Jian Wang, Xin-Ran Tang, Shuai Kang, Qiang John Fu, Chuan-Hui Cao, He-San Luo, Yu-Han Chen, Hong-Bo Zhu, Hong-Hong Yan, Yi-Long Wu, Zhong-Yi Dong
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study Journal for immunotherapy of cancer 8 (1) (2021)
Jin-Ji Yang, Cheng Huang, Yun Fan, Hongming Pan, Jifeng Feng, Liyan Jiang, Xing-Ya Li, Xiao-Qing Liu, Jian-Ping Xiong, Yan-Qiu Zhao, Ying Cheng, Rui Ma, Jie Wang, Yina Wang, Yan-Hui Liu, Dong-Mei Lin, Tao Wang, Wei Shi, Jianjun Zou, Yi-Long Wu
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study. Cancer immunology, immunotherapy : CII (2021)
Lin Shen, Jun Guo, Qingyuan Zhang, Hongming Pan, Ying Yuan, Yuxian Bai, Tianshu Liu, Qing Zhou, Jun Zhao, Yongqian Shu, Xiaoming Huang, Siyang Wang, Jie Wang, Aiping Zhou, Dingwei Ye, Ting Sun, Yujuan Gao, Silu Yang, Zoubai Wang, Jian Li, Yi-Long Wu
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. Journal for immunotherapy of cancer 8 (1) (2021)
Si-Yang Liu, Wen-Zhao Zhong, Yi-Long Wu
What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Hai-Yan Tu, Yang-Si Li, Jin-Ji Yang, Hua-Jun Chen, Ben-Yuan Jiang, Wen-Zhao Zhong, Xue-Ning Yang, Yi-Long Wu
Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report. Clinical drug investigation 41 (5) (2021)
Shouheng Lin, Xuchao Zhang, Guohua Huang, Lin Cheng, Jiang Lv, Diwei Zheng, Simiao Lin, Suna Wang, Qiting Wu, Youguo Long, Baiheng Li, Wei Wei, Pentao Liu, Duan-Qing Pei, Yangqiu Li, Zhesheng Wen, Shuzhong Cui, Peng Li, Xiao-Fang Sun, Yi-Long Wu, Yao Yao
Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells. Oncogene 40 (8) (2021)
Lun-Xi Peng, Guang-Ling Jie, An-Na Li, Si-Yang Liu, Hao Sun, Mei-Mei Zheng, Jia-Ying Zhou, Jia-Tao Zhang, Xu-Chao Zhang, Qing Zhou, Wen-Zhao Zhong, Jin-Ji Yang, Hai-Yan Tu, Jian Su, Hong-Hong Yan, Yi-Long Wu
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors. Experimental hematology & oncology 10 (1) (2021)
Tony S Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Alka Chawla, Rafael Rosell, Jesus Corral, Maria Rita Migliorino, Adam Pluzanski, Kay Noonan, Yiyun Tang, Malaika Pastel, Keith D Wilner, Yi-Long Wu
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs 81 (2) (2021)
Qing Zhou, Lin Wu, Pei Hu, Tongtong An, Jianying Zhou, Li Zhang, Xiao-Qing Liu, Feng Luo, Xin Zheng, Ying Cheng, Nong Yang, Junling Li, Jifeng Feng, Baohui Han, Yong Song, Kai Wang, Li Zhang, Jian Fang, Hong Zhao, Yongqian Shu, Xiao-Yan Lin, Zhihong Chen, Bin Gan, Wan-Hong Xu, Wei Tang, Xiaoying Zhang, Jin-Ji Yang, Xiao Xu, Yi-Long Wu
A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Egbert F Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M Tho, Xiuning Li, Julien Mazieres, Soon Hin How, Masahiro Morise, Viola W Zhu, Daniel Shao-Weng Tan, Kristina H Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M Schumacher, Niki Karachaliou, Yi-Long Wu
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET -amplified NSCLC and first-line osimertinib resistance. Future oncology (London, England) 18 (9) (2021)
Jin-Ji Yang, Jian Fang, Yong-Qian Shu, Jian-Hua Chang, Gong-Yan Chen, Jian Xing He, Wei Li, Xiao-Qing Liu, Nong Yang, Caicun Zhou, Jian An Huang, Melanie M Frigault, Ryan Hartmaier, Ghada F Ahmed, Coumaran Egile, Shethah Morgan, Remy B Verheijen, Anders Mellemgaard, Liu Yang, Yi-Long Wu
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer. Investigational new drugs 39 (2) (2020)
Hai-Yan Tu, Yi-Long Wu
Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data. Future oncology (London, England) 16 (31) (2020)
Hai-Yan Tu, Yi-Long Wu
Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program. OncoTargets and therapy 13 (2020)
Huan Lin, Gong Zhang, Xu-Chao Zhang, Xin-Lei Lian, Wen-Zhao Zhong, Jian Su, Shi-Liang Chen, Yi-Long Wu
Germline variation networks in the PI3K/AKT pathway corresponding to familial high-incidence lung cancer pedigrees. BMC cancer 20 (1) (2020)
Yi-Long Wu, Li Zhang, Yun Fan, JianYing Zhou, Li Zhang, Qing Zhou, Wei Li, ChengPing Hu, GongYan Chen, Xin Zhang, CaiCun Zhou, Thao Dang, Sara Sadowski, Debra A Kush, Yu Zhou, Ben Li, Tony Mok
Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study. International journal of cancer 148 (9) (2020)
Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, Song-Tao Xu, Lin Wu, Yu-Cheng Wei, Yong-Yu Liu, Chun Chen, Ying Cheng, Rong Yin, Fan Yang, Sheng-Xiang Ren, Xiao-Fei Li, Jian Li, Cheng Huang, Zhi-Dong Liu, Shun Xu, Ke-Neng Chen, Shi-Dong Xu, Lun-Xu Liu, Ping Yu, Bu-Hai Wang, Hai-Tao Ma, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-Yang Liu, Qing Zhou, Yi-Long Wu
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (7) (2020)
Si-Yang Liu, Hao Sun, Jia-Ying Zhou, Guang-Ling Jie, Zhi Xie, Yang Shao, Xian Zhang, Jun-Yi Ye, Chun-Xiang Chen, Xu-Chao Zhang, Qing Zhou, Jin-Ji Yang, Yi-Long Wu
Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients. Biomarker research 8 (2020)
Xu-Chao Zhang, Jun Wang, Guo-Guang Shao, Qun Wang, Xiaotao Qu, Bo Wang, Christopher Moy, Yue Fan, Zayed Albertyn, Xiayu Huang, Jingyu Zhang, Yang Qiu, Suso Platero, Matthew V Lorenzi, Enrique Zudaire, Jennifer Yang, Ying Cheng, Lin Xu, Yi-Long Wu
Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. Nature communications 10 (1) (2019)

Yi-Long Wu.css-eqlu8i{font-size:small;padding-left:4px;} (Yilong Wu)

Publication Activity (10 Years)

Top Topics

Top Venues

Yi-Long Wu (Yilong Wu)